secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132783
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM
--------------------------------------------------------------------------

- Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.
- Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.
- No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.
- Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/0001193125-25-132783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/d945167d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer